VAXART INC. - COMMON STOCK

Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate

06 9 2023 15:05:00 提供 Nasdaq GlobeNewswire

Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results

03 8 2023 15:01:00 提供 Nasdaq GlobeNewswire

Vaxart to Host Second Quarter 2023 Business Update and Financial Results Conference Call on August 3

27 7 2023 07:00:01 提供 Nasdaq GlobeNewswire

Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

06 7 2023 07:00:01 提供 Nasdaq GlobeNewswire

Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement

26 6 2023 15:45:00 提供 Nasdaq GlobeNewswire

Vaxart Encourages All Stockholders of Record as of April 28, 2023 to Vote by June 25, 2023, at 11:59 p.m. ET

21 6 2023 15:30:00 提供 Nasdaq GlobeNewswire

Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common Stock

07 6 2023 08:16:01 提供 Nasdaq GlobeNewswire

Vaxart, Inc. Announces Proposed Public Offering of Common Stock

06 6 2023 15:01:27 提供 Nasdaq GlobeNewswire

Vaxart Announces Last Subject Dosed in Phase 2 Trial of its Bivalent Norovirus Candidate, and All Subjects Challenged in Phase 2 Challenge Study of Monovalent Norovirus Candidate

06 6 2023 07:00:01 提供 Nasdaq GlobeNewswire

Vaxart Launches New Investor Communication Program, First Event Scheduled for June 15 at 11 a.m. ET

31 5 2023 07:00:00 提供 Nasdaq GlobeNewswire

Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results  

04 5 2023 15:01:00 提供 Nasdaq GlobeNewswire

Vaxart to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4

28 4 2023 07:00:01 提供 Nasdaq GlobeNewswire

Vaxart to Present at World Vaccine Congress Washington 2023 on April 5-6

29 3 2023 07:00:01 提供 Nasdaq GlobeNewswire

Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus

17 3 2023 07:00:00 提供 Nasdaq GlobeNewswire

Vaxart Provides Business Update and Full Year 2022 Financial Results

15 3 2023 15:01:00 提供 Nasdaq GlobeNewswire

Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15

08 3 2023 15:05:14 提供 Nasdaq GlobeNewswire

Vaxart Doses First Subject in the Phase 2 Clinical Trial of its Bivalent Norovirus Candidate

14 2 2023 07:00:01 提供 Nasdaq GlobeNewswire

Vaxart Names Phillip Lee as Chief Financial Officer

19 12 2022 07:00:00 提供 Nasdaq GlobeNewswire

Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers

01 12 2022 07:00:01 提供 Nasdaq GlobeNewswire

Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29

22 11 2022 07:30:00 提供 Nasdaq GlobeNewswire